HIMS Stock Today (November 18, 2025): Buyback, GLP‑1 Price War and What It Means for Hims & Hers Investors

On Tuesday, November 18, 2025, Hims & Hers Health (NYSE: HIMS) is trading in the shadow of a sharp sell‑off, a fresh $250 million share repurchase authorization, and escalating price competition in the weight‑loss drug market. Together, these forces are shaping how traders and long‑term investors are thinking about HIMS stock today.

HIMS stock price snapshot for November 18, 2025

As of the latest available data, Hims & Hers shares closed on Monday, November 17 at $35.58, down 3.79% on the day. Pre‑market indications early Tuesday showed the stock changing hands around $35.00, about 1.6% lower from Monday’s close, suggesting a cautious open for today’s session. ^[1]

Despite the recent slide, HIMS is still having a big year:

The stock is up roughly 70% over the past 12 months, even after a steep pullback. ^[2]
Over the past month, shares have fallen about 29%, reflecting how violently sentiment has reversed. ^[3]
At around current levels, HIMS trades at a price‑to‑earnings ratio of about 60.5x, far above the ~17x multiple typical for U.S. stocks, underscoring that the market still prices in strong growth. ^[4]
On a EV‑to‑revenue basis, Hims & Hers is at about 3.9x, according to GuruFocus, a mid‑range valuation for a fast‑growing digital health name. ^[5]

Short‑term algorithmic models, such as CoinCodex’s daily forecast, point to relatively flat near‑term moves, with a projected price of roughly $35.6 for November 18 and only modest upside in the following days. These model-driven forecasts can shift quickly and should be treated as rough indications, not guarantees. ^[6]

The big catalyst: A new $250 million HIMS share buyback

The headline fundamental story investors are digesting today is Hims & Hers’ new $250 million share repurchase program.

Key details of the buyback

On November 17, 2025, Hims & Hers announced that its board authorized a new repurchase program of up to $250 million of Class A common stock, to be executed over the next three years. ^[7]
The program follows the full utilization of a prior $100 million buyback, launched in July 2024. Between October 1 and November 7, the company repurchased 1,334,572 shares for $55.5 million, exhausting the remaining capacity of that earlier plan. ^[8]
Repurchases may occur via open‑market trades, privately negotiated transactions, or Rule 10b5‑1 trading plans, and the board can suspend or cancel the program at any time. ^[9]
CEO Andrew Dudum framed the move as an opportunity to “capitalize on valuation disconnects” given the company’s strong balance sheet and projected cash flows, underscoring management’s view that the stock is undervalued at current levels. ^[10]

An Investing.com recap noted that the stock initially traded up about 1.5% after the buyback was announced, before broader GLP‑1 headlines dragged it back into the red. ^[11] Official end‑of‑day data, however, show HIMS closing down nearly 3.8% at $35.58, highlighting how quickly sentiment shifted intraday. ^[12]

Why the buyback matters

For investors, this new authorization is important for a few reasons:

It signals confidence: management is willing to deploy substantial capital to repurchase shares at current prices, even after a massive run‑up earlier in the year. ^[13]
It offers downside support: consistent buybacks can help absorb selling pressure and incrementally support earnings per share.
It competes with growth investments: every dollar spent on buybacks is a dollar not spent on R&D, marketing or acquisitions, so investors will watch how aggressively Hims uses the authorization versus reinvesting in the business.

In short, the buyback gives Hims & Hers a flexible tool, but whether it becomes a true tailwind for the share price will depend on how the program is executed – and how the company’s fundamentals evolve from here.

GLP‑1 price war: Novo’s cuts overshadow the buyback

The main reason HIMS stock sold off even as the buyback news hit the tape is the escalating price war in GLP‑1 obesity drugs, where Hims & Hers is trying to carve out a position.

A TradingView/StockStory note on Monday reported that Hims & Hers shares fell roughly 4.9% in afternoon trading after news that Novo Nordisk would cut U.S. self‑pay prices on its GLP‑1 blockbusters Wegovy and Ozempic, with reductions from about $499 to $349 per month for certain offerings. ^[14]

Separately, coverage from Business of Fashion today highlights that Novo is experimenting with even lower introductory pricing around GLP‑1 treatments, seeking to defend share as competition intensifies and more telehealth players push “affordable” obesity‑care bundles. ^[15]

For Hims & Hers, this matters because:

The company increasingly leans on GLP‑1‑based weight‑loss treatments—including compounded semaglutide and planned “microdosing” regimens—as a major growth driver. ^[16]
A more aggressive pricing stance from Novo and rivals could compress margins across the ecosystem or force Hims to compete more heavily on service experience and convenience rather than price alone.
The GLP‑1 narrative has been a big part of why HIMS rerated earlier this year, so any perception of crowded competition or shrinking economics can quickly hit the stock. ^[17]

Monday’s trading told that story: investors appeared more focused on the GLP‑1 price squeeze than on the supportive optics of a big buyback.

Q3 2025 earnings: big growth, but guidance and profit raised questions

Underneath the volatility, the third‑quarter 2025 results are still the fundamental anchor for Hims & Hers’ story heading into today.

Top‑line and subscriber growth

For Q3 2025 (reported on November 3):

Revenue reached about $599 million, up ~49% year‑over‑year, and ahead of analyst expectations in the $579–580 million range. ^[18]
Subscribers climbed to roughly 2.5 million, an increase of about 21% versus a year earlier. ^[19]
Average monthly revenue per user rose around 19% to about $80, helped by higher adoption of specialty offerings like GLP‑1 treatments and more comprehensive care bundles. ^[20]

Profitability and guidance

On the bottom line:

GAAP net income came in at about $15.8 million, down sharply from roughly $75.6 million in Q3 2024, when results had been boosted by a large one‑time item. ^[21]
Adjusted EBITDA exceeded $78 million, beating expectations and delivering a margin just over 13%. ^[22]
Adjusted EPS of $0.06 missed consensus estimates of around $0.10, signaling that heavy investment is still biting into earnings. ^[23]

Management narrowed full‑year 2025 revenue guidance to about $2.335–$2.355 billion, and adjusted EBITDA guidance to $307–$317 million, still implying robust growth but slightly under some earlier market expectations. ^[24]

In commentary reported by Reuters and Investors.com, CEO Andrew Dudum reiterated a long‑term revenue goal of roughly $6.5 billion by 2030, with a substantial contribution expected from GLP‑1 drugs and related metabolic care offerings. ^[25]

Labs: Hims’ new “affordable” testing platform

Another key piece of the HIMS narrative investors are watching today is Labs, Hims & Hers’ new subscription‑based diagnostic product.

According to TipRanks’ coverage: ^[26]

Labs is billed as an “affordable” platform that turns what used to be premium lab work—covering heart health, metabolism, inflammation, hormone levels and more—into a subscription service, with clear explanations of results and personalized action plans created with physicians.
Annual plans are structured around tiered access to biomarker testing and virtual clinical follow‑up, designed to deepen engagement and cross‑sell additional treatments. ^[27]

However, the same report flagged mixed engagement trends:

App downloads were down about 21% year‑over‑year at the end of October.
Web traffic to Hims & Hers platforms declined around 14%. ^[28]

Despite those headwinds, subscriber counts and revenue have continued to climb, suggesting that while top‑of‑funnel traffic has softened, Hims is extracting more value from its existing user base through richer offerings like Labs and GLP‑1 programs. ^[29]

Valuation today: expensive, but with a growth case

The sell‑off into mid‑November has forced investors to reconsider where HIMS belongs on the growth/value spectrum.

A fresh valuation piece from Simply Wall St, published today, notes that: ^[30]

Hims & Hers shares have gained about 70% over the last year, but fallen roughly 29% this past month.
At current prices, HIMS trades on a P/E of about 60.5x, much higher than the U.S. market median.
Consensus forecasts call for earnings growth of roughly 24% per year over the next three years, more than double the broader market’s roughly 11% expectation—an argument for why investors might still be willing to pay a premium.

On the Wall Street side, TipRanks summarises the consensus rating on HIMS as “Hold”: ^[31]

10 analysts have weighed in over the last three months: 2 Buys, 6 Holds, 2 Sells.
The average price target is about $48.57, implying roughly 34% upside from current levels.
Even after a 39% drop over the past three months, shares are still up around 50% year‑to‑date.

A Seeking Alpha note from Tech Stock Pros last week upgraded HIMS to a more bullish stance, arguing that: ^[32]

The worst of the de‑rating appears “priced in”.
Q3 results reinforced that the growth story is bigger than GLP‑1 alone, centered on personalized “fast‑fashion healthcare” bundles across multiple conditions.
International expansion and new verticals (testosterone therapy, menopause care, diagnostics) could support further upside into 1H 2026 if execution holds.

Together, these views suggest that HIMS is no longer a pure momentum story: the market is wrestling with how much to pay for fast growth that is also increasingly exposed to competition, regulation and legal scrutiny.

Regulatory and legal backdrop: new policy chief, old headaches

Regulation has become a critical part of the Hims & Hers investment debate, particularly around GLP‑1 marketing and compounded semaglutide.

New chief policy officer

On November 17, Reuters reported that Hims & Hers appointed Deb Autor as its first chief policy officer, overseeing public policy and government engagement. ^[33]

Autor is a former deputy commissioner for global regulatory operations and policy at the U.S. FDA, and also previously held a senior role at AstraZeneca. ^[34]
She has served on Hims & Hers’ board since 2024 and will retain that seat while taking on the new executive role. ^[35]
The appointment comes after the FDA raised concerns over “misleading marketing” in some Hims campaigns, and as regulators scrutinize telehealth companies’ role in prescribing GLP‑1 therapies and compounded semaglutide. ^[36]

For investors today, this hire is a clear sign that Hims is professionalizing its regulatory strategy, which could reduce headline risk over time—but also underscores how material those regulatory risks have become.

Shareholder lawsuits and investigations

Hims & Hers has also been the target of securities class action filings and board investigations in recent months, focused mainly on alleged misstatements around its past partnership with Novo Nordisk and the GLP‑1 franchise. ^[37]

While these cases are still in progress and outcomes are uncertain, they add an extra layer of risk that investors in HIMS need to factor into their analysis today.

Institutional flows: a fresh $4 million position

On the ownership front, a new MarketBeat alert dated November 18, 2025 notes that quantitative manager Intech Investment Management LLC holds a stake of about $4.03 million in Hims & Hers Health. ^[38]

Details of position sizing (in shares) and timing aren’t fully visible from the snippet, but the filing highlights that systematic and institutional investors remain active in the name despite recent volatility.

What to watch next if you own (or are eyeing) HIMS stock

For traders and long‑term shareholders looking at HIMS today, November 18, 2025, a few themes are front and center:

Execution of the $250M buyback
- Does management deploy the authorization aggressively at current prices, or keep it mostly as dry powder?
- Future 10‑Q filings and disclosures will reveal how much capital is actually returned via repurchases. ^[39]
GLP‑1 landscape and pricing
- Novo Nordisk’s latest price cuts and any competitive response from Eli Lilly or others. ^[40]
- How Hims & Hers prices its microdose GLP‑1 treatments and any eventual branded Wegovy offerings, if negotiations with Novo lead to a deal. ^[41]
Labs adoption and engagement trends
- Whether Labs can re‑accelerate app downloads and web traffic or at least deepen monetization of the existing subscriber base. ^[42]
Regulatory developments
- Any new guidance from the FDA on telehealth prescribing and compounded GLP‑1 medications. ^[43]
- How quickly Deb Autor’s policy team can reduce the risk of future enforcement actions or marketing controversies. ^[44]
Sentiment shifts and analyst moves
- Changes in the consensus rating or price targets, especially after the buyback announcement and GLP‑1 price moves. ^[45]
- Whether a prolonged pullback tempts more value‑oriented or growth‑at‑a‑reasonable‑price (GARP) investors into the name.

Bottom line: HIMS on November 18, 2025

Today, Hims & Hers sits at a crossroads:

The company is delivering rapid revenue and subscriber growth, expanding into diagnostics and new care verticals, and backing its confidence with a $250 million buyback authorization. ^[46]
At the same time, the stock is grappling with a bruising month‑long sell‑off, an intensifying GLP‑1 price war, regulatory overhangs, and an expensive valuation multiple that leaves little room for execution missteps. ^[47]

For investors, HIMS on November 18, 2025 is neither a simple growth fairy tale nor a clear‑cut value play—it’s a high‑beta, execution‑sensitive story where news flow around GLP‑1 pricing, regulatory scrutiny and buyback activity can move the stock quickly in either direction.

As always, this overview is for informational purposes only and is not financial advice. Anyone considering HIMS should do their own research, review the company’s filings, and consider speaking with a qualified financial adviser before making investment decisions.

Hims & Hers' Next 10x Opportunity